Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis

Shigeaki Suzuki; Tetsuya Nishimoto; Mitsutomo Kohno; Kimiaki Utsugisawa; Yuriko Nagane; Masataka Kuwana; Norihiro Suzuki

doi:10.1016/j.jneuroim.2013.03.001

Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis

Shigeaki Suzuki, Tetsuya Nishimoto, Mitsutomo Kohno, Kimiaki Utsugisawa, Yuriko Nagane, Masataka Kuwana, Norihiro Suzuki

内科学(神経)

研究成果: Article › 査読

13 被引用数 (Scopus)

抄録

There are no immunological markers to predict the prognosis of thymoma-associated myasthenia gravis (MG). Clinical and immunological factors associated with thymoma recurrence or MG relapse were examined by logistic analyses in 56 Japanese patients with thymoma-associated MG. Patients with anti-Kv1.4 antibodies showed higher frequencies of thymoma recurrence and MG relapse compared to those without. Anti-Kv1.4 antibody, Masaoka stage 4, World Health Organization type B3, and adjuvant radiotherapy were associated with thymoma recurrence. Multivariate analyses showed that anti-Kv1.4 antibody was the only independent factor associated with MG relapse. Anti-Kv1.4 antibody is a useful predictor of the prognosis of thymoma-associated MG.

本文言語	English
ページ（範囲）	61-66
ページ数	6
ジャーナル	Journal of Neuroimmunology
巻	258
号	1-2
DOI	https://doi.org/10.1016/j.jneuroim.2013.03.001
出版ステータス	Published - 2013

ASJC Scopus subject areas

免疫アレルギー学
免疫学
神経学
臨床神経学

文献へのアクセス

10.1016/j.jneuroim.2013.03.001

他のファイルとリンク

引用スタイル

@article{5d9d65ca894b48b4a2e3d6e14322c0ba,

title = "Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis",

abstract = "There are no immunological markers to predict the prognosis of thymoma-associated myasthenia gravis (MG). Clinical and immunological factors associated with thymoma recurrence or MG relapse were examined by logistic analyses in 56 Japanese patients with thymoma-associated MG. Patients with anti-Kv1.4 antibodies showed higher frequencies of thymoma recurrence and MG relapse compared to those without. Anti-Kv1.4 antibody, Masaoka stage 4, World Health Organization type B3, and adjuvant radiotherapy were associated with thymoma recurrence. Multivariate analyses showed that anti-Kv1.4 antibody was the only independent factor associated with MG relapse. Anti-Kv1.4 antibody is a useful predictor of the prognosis of thymoma-associated MG.",

keywords = "Anti-Kv1.4 antibody, Myasthenia gravis, Prognosis, Thymoma",

author = "Shigeaki Suzuki and Tetsuya Nishimoto and Mitsutomo Kohno and Kimiaki Utsugisawa and Yuriko Nagane and Masataka Kuwana and Norihiro Suzuki",

note = "Funding Information: This work was supported by a grant from the Japanese Ministry of Education, Science, Sports and Culture (no. 23591255) and a Neuroimmunological Disease Research Committee grant from the Japanese Ministry of Health, Labour, and Welfare.",

year = "2013",

doi = "10.1016/j.jneuroim.2013.03.001",

language = "English",

volume = "258",

pages = "61--66",

journal = "Advances in Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis

AU - Suzuki, Shigeaki

AU - Nishimoto, Tetsuya

AU - Kohno, Mitsutomo

AU - Utsugisawa, Kimiaki

AU - Nagane, Yuriko

AU - Kuwana, Masataka

AU - Suzuki, Norihiro

N1 - Funding Information: This work was supported by a grant from the Japanese Ministry of Education, Science, Sports and Culture (no. 23591255) and a Neuroimmunological Disease Research Committee grant from the Japanese Ministry of Health, Labour, and Welfare.

PY - 2013

Y1 - 2013

N2 - There are no immunological markers to predict the prognosis of thymoma-associated myasthenia gravis (MG). Clinical and immunological factors associated with thymoma recurrence or MG relapse were examined by logistic analyses in 56 Japanese patients with thymoma-associated MG. Patients with anti-Kv1.4 antibodies showed higher frequencies of thymoma recurrence and MG relapse compared to those without. Anti-Kv1.4 antibody, Masaoka stage 4, World Health Organization type B3, and adjuvant radiotherapy were associated with thymoma recurrence. Multivariate analyses showed that anti-Kv1.4 antibody was the only independent factor associated with MG relapse. Anti-Kv1.4 antibody is a useful predictor of the prognosis of thymoma-associated MG.

AB - There are no immunological markers to predict the prognosis of thymoma-associated myasthenia gravis (MG). Clinical and immunological factors associated with thymoma recurrence or MG relapse were examined by logistic analyses in 56 Japanese patients with thymoma-associated MG. Patients with anti-Kv1.4 antibodies showed higher frequencies of thymoma recurrence and MG relapse compared to those without. Anti-Kv1.4 antibody, Masaoka stage 4, World Health Organization type B3, and adjuvant radiotherapy were associated with thymoma recurrence. Multivariate analyses showed that anti-Kv1.4 antibody was the only independent factor associated with MG relapse. Anti-Kv1.4 antibody is a useful predictor of the prognosis of thymoma-associated MG.

KW - Anti-Kv1.4 antibody

KW - Myasthenia gravis

KW - Prognosis

KW - Thymoma

UR - http://www.scopus.com/inward/record.url?scp=84876716596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876716596&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2013.03.001

DO - 10.1016/j.jneuroim.2013.03.001

M3 - Article

C2 - 23561592

AN - SCOPUS:84876716596

SN - 0165-5728

VL - 258

SP - 61

EP - 66

JO - Advances in Neuroimmunology

JF - Advances in Neuroimmunology

IS - 1-2

ER -

Clinical and immunological predictors of prognosis for Japanese patients with thymoma-associated myasthenia gravis

抄録

ASJC Scopus subject areas

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル